Cargando…
Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype
BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing globally. Barrett’s oesophagus (BO) is a pre-malignant condition with no biomarker to risk stratify those at highest risk of dysplasia and malignant transformation. METHODS: Subcellular epithelial protein (HMGB1, p53, RUNX3) expre...
Autores principales: | Porter, Ross J., Murray, Graeme I., Brice, Daniel P., Petty, Russell D., McLean, Mairi H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028982/ https://www.ncbi.nlm.nih.gov/pubmed/31831860 http://dx.doi.org/10.1038/s41416-019-0685-1 |
Ejemplares similares
-
RADIOFREQUENCY ABLATION AND ENDOSCOPIC MUCOSAL IN TREATMENT OF EARLY NEOPLASTIC BARRETT’S OESOPHAGUS
por: Callaghan, B, et al.
Publicado: (2018) -
Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an ‘Immune Cold’ Phenotype Associated with Poor Survival
por: Porter, Ross J., et al.
Publicado: (2023) -
Update on endoscopic treatment of Barrett’s oesophagus and Barrett’s oesophagus–related neoplasia
por: Pech, Oliver, et al.
Publicado: (2020) -
Biomarkers for Risk Stratification of Neoplastic Progression in Barrett Esophagus
por: Kerkhof, Marjon, et al.
Publicado: (2007) -
Barrett's oesophagus and adenocarcinoma
por: Caygill, Christine PJ, et al.
Publicado: (2004)